SPTX (Seaport Therapeutics) Stock Based Compensation: $6.88 Mil (TTM As of Dec. 2025)


SPTX Seaport Therapeutics Inc SPTX
11 GF Score
Price $21.43
! 1 Warning Sign
View Full Analysis

What is Seaport Therapeutics Stock Based Compensation?

Seaport Therapeutics SPTX +10.37% 11 Stock Based Compensation is $6.88 Mil as of Dec. 2025. GuruFocus rates SPTX with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Seaport Therapeutics's Stock Based Compensation for the six months ended in Dec. 2025 was $6.88 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was $6.88 Mil.

Seaport Therapeutics Stock Based Compensation Related Terms

Seaport Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Seaport Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seaport Therapeutics Stock Based Compensation Chart

Seaport Therapeutics Annual Data
Trend Dec24 Dec25
Stock Based Compensation
14.52 6.88

Seaport Therapeutics Semi-Annual Data
Dec24 Dec25
Stock Based Compensation 14.52 6.88
SPTX
11GF Score
Seaport Therapeutics Inc SPTX
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Seaport Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was $6.88 Mil.

What does a Stock Based Compensation of $6.88 Mil mean?
Seaport Therapeutics (SPTX) has a Stock Based Compensation of $6.88 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Seaport Therapeutics and its competitors.
Is Seaport Therapeutics' Stock Based Compensation too high?
Seaport Therapeutics' current Stock Based Compensation is $6.88 Mil. Overall, Seaport Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Seaport Therapeutics' Stock Based Compensation compare to LXRX and DRTS?
Seaport Therapeutics' Stock Based Compensation of $6.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Seaport Therapeutics and its competitors. Seaport Therapeutics's current Stock Based Compensation is $6.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seaport Therapeutics stock overvalued right now?
Seaport Therapeutics (SPTX) has a current Stock Based Compensation of $6.88 Mil. The current Stock Based Compensation is $6.88 Mil. Seaport Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Seaport Therapeutics (SPTX), the current Stock Based Compensation is $6.88 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Seaport Therapeutics Business Description

Address 101 Seaport Boulevard, Floor 12, Boston, MA, USA, 02210
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
11GF Score

Get the complete analysis for SPTX

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.43
Price